Dear Editor,

Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction \[[@CR1]\]. Immunoglobulin D (IgD) myeloma is a rare subtype of MM, accounting for approximately 1% to 2% of all MM patients \[[@CR2]\]. It occurs at a young age, often accompanied with a high disease burden and short median survival (18--21 months) \[[@CR3], [@CR4]\]. Several studies have suggested that in patients with IgD subtype, the outcomes of those who have had undergone autologous stem cell transplantation (ASCT) were superior than those treated with chemotherapy alone \[[@CR5], [@CR6]\]. However, these have been debatable as other reports have displayed opposite results \[[@CR7], [@CR8]\].

In the last decade, novel agents such as proteasome inhibitor and immunomodulatory agents have been used to treat MM, which have resulted in a 50% improvement in the patients' overall survival (OS: 44.8 vs. 29.9 months) \[[@CR9]\]. However, given the rarity of IgD myeloma, studies on it remain rare. Knowledge about this subtype was mostly derived from few single-center case series. In China, there has been no report to fully elucidate on whether the results of survival outcomes for patients with IgD subtype from novel agents could be replicated in those with non-IgD subtypes. Here, we performed a retrospective analysis on 216 symptomatic MM patients, diagnosed from August 2006 to April 2018, at the Jinling Hospital (Nanjing, Jiangsu, China). The patient cohort comprised of 13 with IgD subtype and 203 with non-IgD subtypes. Three new drugs, bortezomib, thalidomide, and lenalidomide, were used as induction therapy choice, based on which we investigated their clinical manifestations, treatment responses, and outcomes. In this study cohort, 1 patient with IgD subtype and 11 with non-IgD subtypes underwent ASCT.

First, we compared the clinical features between the IgD and non-IgD subtypes (Table [1](#Tab1){ref-type="table"}). The median age of onset for the IgD subtype was 52 years, which was younger than that of the non-IgD subtypes (60 years, *P* = 0.028). The rate of λ light chain was significantly higher in patients with the IgD subtype than in those with non-IgD subtypes (92.3% vs. 48.8%, *P* = 0.006). Moreover, as compared with non-IgD subtypes, patients with IgD subtype presented more often with significant renal dysfunction (creatinine \> 2 mg/L, *P* \< 0.001) and amyloid light-chain (AL) amyloidosis (*P* = 0.001) and had higher frequencies of critical clinical features such as International staging system (ISS)-III disease (*P* = 0.002), severe anemia (Hemoglobin \< 90 g/L, *P* = 0.011), high β~2~ microglobulin (β~2~Μ) concentration (*P* = 0.001), and elevated lactate dehydrogenase (LDH \> 250 U/L, *P* = 0.002). However, there were no significant differences in sex, platelet counts, bone lesion, hypercalcemia, urine protein, induction therapy, and extramedullary infiltration between IgD and non-IgD subtypes.Table 1Clinical characteristics and treatment of 216 patients with multiple myelomaCharacteristicsIgD subtypeNon-IgD subtypes*P* valueCases, *n*13203Age \[years; median (range)\]52 (44--66)60 (24--82)0.028Sex \[cases (%)\]0.782 Male8 (61.5)117 (57.3) Female5 (38.5)86 (42.7)Hemoglobin \[g/L; mean (range)\]73 (44--108)90 (40--107)0.011Platelets \< 100 × 10^9^/L \[cases (%)\]4 (30.8)32 (15.8)0.306Light chain type \[cases (%)\]0.006 κ1 (7.7)104 (51.2) λ12 (92.3)99 (48.8)Creatinine \> 2 mg/dL \[cases (%)\]9 (69.2)47 (23.2)\< 0.001β~2~M \[mg/L; mean (range)\]10 (2.57--16.50)5.16 (1.45--19.40)0.001Bone lesion \[cases (%)\]10 (76.9)170 (83.7)0.459Hypercalcemia \[cases (%)\]3(23.1)14 (6.9)0.117Urine protein (g/L)3.20 (0.15--19.69)1.30 (0.10--26.10)0.196LDH \> 250 U/L \[cases (%)\]7 (53.8)37 (18.2)0.002ISS stage \[cases (%)\]0.002 I041 (20.2) II058 (28.6) III13 (100.0)104 (50.2)Induction therapy \[cases (%)\]0.080 IMiD-based regimens4 (30.8)121(59.6) Bortezomib-based regimens9 (69.2)82 (40.4)Final response \[cases (%)\]0.847 sCR, CR4 (30.8)68 (33.5) VGPR3 (23.1)80 (39.4) PR4 (30.8)43 (20.9) SD plus PD2 (15.4)12 (5.8)AL amyloidosis \[cases (%)\]4 (30.8)8 (3.9)0.001Extramedullary infiltration \[cases (%)\]2 (15.4)57 (28.1)0.500*IgD* immunoglobulin D, *β*~*2*~*M* β~2~ microglobulin, *LDH* lactate dehydrogenase, *ISS* international staging system, *IMiD* immunomodulatory drug, *sCR* strict complete response, *CR* complete response, *VGPR* very good partial response, *PR* partial response, *SD* stable disease, *PD* progressive disease, *AL* amyloidosis amyloid light-chain amyloidosis

Based on the data from Table [2](#Tab2){ref-type="table"}, we found that 30.8% (4/13) of patients with IgD subtype presented with significant abnormalities in serum-free light chain (sFLC) ratio (\< 0.01 or \> 100) at baseline, compared with 7.5% (13/173) for the non-IgD subtypes (*P *= 0.021). Moreover, about half of those (46.2%) with IgD subtype showed an obvious increase in sFLC ratio abnormalities when relapsed (*P *\< 0.001).Table 2The sFLC concentrations and abnormal ratios of the investigated 186 patientsVariableBaselineAfter relapseIgD subtype (*n* = 13)Non-IgD subtypes (*n *= 173)^a^*P* valueIgD subtype (*n *= 13)Non-IgD subtypes (*n *= 96)*P* valuesFLC \[mg/L; median (range)\] κ12.10 (8.54--186.40)25.80 (1.49--17,780.00)0.56715.60 (8.50--1708.00)56.00 (7.49--4541.00)0.655 λ129.70 (8.46--4303.00)28.80 (1.33--17,600.00)0.151583.86 (10.51--1092.00)687.00 (1.33--4000.00)0.412κ/λ \< 0.01 or \> 100 \[cases (%)\]4 (30.78)13 (7.51)0.0216 (46.15)7 (7.29)\< 0.001*sFLC* serum free light chain, *IgD* immunoglobulin D^a^Serum-free light chains were only available for 173 cases of MM patients at the time of diagnosis

Of the 216 MM patients, 198 (91.7%) were subjected to cytogenetic abnormality testing (Table [3](#Tab3){ref-type="table"}). 1q21 amplification was discovered in 9 patients with IgD subtype, which was higher than that in patients with non-IgD subtypes (75.0% vs. 40.3%, *P *= 0.018). The rate of t (14;16) was also significantly higher in patients with IgD subtype than those with the non-IgD subtypes (17.0% vs. 1.6%, *P *= 0.023). However, no significant differences in other cytogenetic abnormalities such as 13 deletions, t (4;14), t (11;14), p53 deletion, and hyperdiploid between the IgD and non-IgD subtypes were found.Table 3Abnormal cytogenetic characteristics in 198 case of MM patientsVariableIgD subtype \[cases (%)\]Non-IgD subtypes \[cases (%)\]*P* valueTotal1218613 deletion4 (33.3)59 (31.7)0.9071q21 amplification9 (75.0)75 (40.3)0.018IGH rearrangement6 (50.0)59 (31.7)0.191 t(4;14)3 (25.0)31 (16.7)0.729 t(11;14)1 (8.0)25 (13.4)0.866 t(14;16)2 (17.0)3 (1.6)0.023p53 deletion0 (0)7 (3.8)1.000Hyperdiploid4 (33.3)71 (38.2)0.948*IgD* immunoglobulin D, *IGH* immunoglobulin heavy chain gene

Second, we analyzed the treatment response between the IgD and non-IgD subtypes and have listed their detailed information regarding the treatment and survival of the patients with IgD subtype in Table [4](#Tab4){ref-type="table"}. By the end of follow-up on August 31, 2018, 71 deaths were recorded of whom 9 cases (69.2%) were from patients having the IgD subtype. The overall response rate of the entire cohort was 93.5% (202/216). Response of induction therapy for the IgD subtype was similar to that of the non-IgD subtypes (*P *= 0.847, Table [1](#Tab1){ref-type="table"}). However, the median duration of response in patients with IgD subtype was 10 months, which was significantly shorter than that of patients with non-IgD subtypes (23.6 months, *P *= 0.002) (Fig. [1](#Fig1){ref-type="fig"}a). The median follow-up of the 216 patients was 32.4 months (range 0.96--147 months). In patients with IgD subtype, the median progression-free survival (PFS) was 10.0 months and the median OS was 22.9 months, compared with 27.9 months (*P *= 0.003; Fig. [1](#Fig1){ref-type="fig"}b) and 81.7 months (*P *\< 0.001; Fig. [1](#Fig1){ref-type="fig"}c) for patients bearing the non-IgD subtypes.Table 4Treatment and survival of the 13 patients with IgD subtype MMPatient no.ISS stageSexAge (years)Introduction therapy/cyclesResponseTherapy after PD/cyclesSurvival statusPFS (months)OS (months)1IIIMale51CTD/5CRRAD/6Alive6.017.62IIIFemale53CTD/7PRRD/8Alive8.019.53IIIMale64VCD/1PDNADead0.70.94IIIMale48VTD/8PRRCDDead26.244.35IIIFemale59VTD/2SDNADead5.15.76IIIMale44VCD/9CRTAD/6 + RAD/6Alive42.347.07IIIFemale49VTD/9CRRAD/10Dead28.042.68IIIMale52VCD/9VGPRRD/6Dead8.513.09IIIMale45VCD/2CRCTD/8Alive2.49.210IIIMale59VD/4PRVCTD/5Dead16.716.711IIIMale51CTD/5PRRAD/3Dead10.06.612IIIFemale56VCD/4 + ASCTVGPRCTD/4Dead18.722.913IIIFemale66VD/4VGPRRD/6Dead48.066.0*IgD* immunoglobulin D, *ISS* international staging system, *PD* progressive disease, *PFS* progression-free survival, *OS* overall survival, *CTD* thalidomide + cyclophosphamide + dexamethasone, *CR* complete response, *RAD* lenalidomide + adriamycin + dexamethasone, *PR* partial response, *RD* lenalidomide + dexamethasone, *VCD* bortezomib + cyclophosphamide + dexamethasone, *PD* progressive disease, *NA* not applicable, *VTD* bortezomib + thalidomide + dexamethasone, *RCD* lenalidomide + cyclophosphamide + dexamethasone, *SD* stable disease, *TAD* thalidomide + adriamycin + dexamethasone, *VGPR* very good partial response, *VD* bortezomib + dexamethasone, *VCTD* bortezomib + thalidomide + cyclophosphamide + dexamethasone, *ASCT* autologous stem cell transplantation Fig. 1**a** Duration of response in patients with IgD subtype or non-IgD subtypes of multiple myeloma, **b** Kaplan--Meier progression-free survival curves of patients with IgD subtype or non-IgD subtypes of multiple myeloma, **c** Kaplan--Meier overall survival curves of patients with IgD subtype or non-IgD subtypes of multiple myeloma

Lastly, we analyzed the other risk factors that might have affected the prognoses of the investigated MM patients (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Univariate analyses showed that, besides the IgD subtype, patients with high β~2~M level, elevated LDH level, having extramedullary infiltration, ISS stage III, 13q deletion, 1q21 amplification, IGH rearrangement, and abnormal sFLC ratio had shorter OS compared with their counterparts (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). Multivariate analyses showed that IgD subtype was an independent adverse factor for both PFS (*P *= 0.009) and OS (*P *= 0.001) (Table [5](#Tab5){ref-type="table"}).Table 5Multivariate analysis for PFS and OS of 216 patients with multiple myelomaVariablePFSOSHR95% CI*P* valueHR95% CI*P* valueLDH \> 250 U/L1.4941.020--2.1890.0392.7911.692--4.604\< 0.001ISS stage III1.2981.032--1.6330.0261.5331.096--2.1450.013IgD subtype2.2211.221--4.0400.0093.5061.687--7.2850.0011q21 amplification------1.9491.179--3.2240.009IGH rearrangement1.6151.260--2.071\< 0.0011.4851.165--1.8950.001Extramedullary infiltration2.0841.421--3.055\< 0.0013.6922.199--6.200\< 0.001*PFS* progression-free survival, *OS* overall survival, *HR* hazard ratio, *CI* confidence interval, *LDH* lactate dehydrogenase, *ISS* international staging system, *IgD* immunoglobulin D, *IGH* immunoglobulin heavy chain gene

The synthesis rate of IgD is very low in patients bearing the IgD subtype, which often leads to missed diagnosis \[[@CR2]\]. Among the 216 MM patients, 13 had IgD subtype (6%). This proportion was similar to another report in China (5.4%) \[[@CR8]\] but was slightly higher than that observed in western countries (1%--2%) \[[@CR2]\]. Nevertheless, the proportion of IgD subtype may still be underestimated, therefore, identifying and understanding this disease is extremely essential.

It has been reported that the IgD subtype of MM occurred more often in young patients, with a median age of 52 to 60 years. Moreover, it was found to be associated with higher β~2~M, extramedullary involvement, secondary systemic amyloidosis, a λ light chain bias (IgD myeloma is characterized by the presence of a predominance of λ over K light chain type), renal failure, and short survival \[[@CR3]\]. The clinical characteristics of our patients were similar to the results of the above-mentioned studies.

In addition, we interestingly found that patients with the IgD subtype demonstrated significant sFLC ratio abnormalities at baseline and during disease relapse, especially in the 46.2% of patients with disease relapse. This finding may be conducive to assess the disease progression and to identify early relapse for timely intervention. Moreover, as compared to the IgD subtype patients with abnormal sFLC ratio, those with normal sFLC ratio had a numerically superior OS (42.56 months vs. 5.7 months, *P *= 0.057, Additional file [3](#MOESM3){ref-type="media"}: Figure S2). There was noted solely as a tendency, which may have been most likely due to the small cohort size.

High-risk cytogenetic abnormalities in MM patients with IgD subtype have been reported to range from 30 to 50%. In our study, 1q21 amplification was observed in 75% of patients with IgD subtype. It was reported that the overexpression of genes mapping to 1q21 could regulate the growth and resistance of MM to drugs, and result in increasing risk of early death of the patients \[[@CR10]\]. Recent research has also found that the adverse effects due to 1q21 amplification on prognosis persisted even after removal of other identified high-risk cytogenetic changes, including p53 deletion, t(4;14), t(14;16), and t(14;20) \[[@CR11]\]. Therefore, the association of IgD MM with a high rate of 1q21 amplification might contribute to poor outcomes. Perhaps it could also explain why patients with IgD subtype and non-IgD subtypes had similar response rates, but different duration of response.

Researchers have tried different ways to improve the prognosis of patients with IgD subtype all along. In 2005, Wechalekar et al. \[[@CR5]\] suggested that the mean OS of IgD subtype patients could be prolonged after ASCT when compared with chemotherapy (5.1 years vs. 2 years, respectively, *P* = 0.090). In 2014, Zagouri et al. \[[@CR12]\] reported a median OS of 51.5 months in 31 IgD subtype patients in Greece, which was the longest survival treated with chemotherapy reported until now. However, in Asia, the data seemed less consistent. In 2008 and 2010, two studies from Korea reported poor outcomes for the IgD subtype patients following ASCT or conventional chemotherapy, with the median OS of 12 and 18.5 months \[[@CR4], [@CR7]\]. In 2015, a report from China showed that the median OS and PFS of IgD subtype were 24 and 15.5 months, respectively and no difference in OS was found among the bortezomib-only group, the non-bortezomib group, and the bortezomib + ASCT group \[[@CR8]\]. Here, our patients with IgD subtype showed similar median OS (22.9 months) and PFS (10 months) as to these studies from Asia. Though patients with non-IgD subtypes had a favourable median OS of 81.7 months in our study, in the era of novel agents, the survival of patients with IgD subtype still cannot be improved from the new drugs, unlike the non-IgD subtypes. Recently, a case report on a patient with IgD subtype who was refractory to at least 5 different chemotherapy regimens had shown very good partial response to daratumumab (anti-CD38 monoclonal antibody) \[[@CR13]\]. We expect that additional agents with novel mechanism including histone deacetylation, target of surface receptors, and chimeric antigen receptor T Cell immunotherapy would improve the survival of IgD subtype patients.

In summary, the IgD subtype was found to be an independent adverse risk factor for prognosis. MM patients with IgD subtype presented with a more aggressive disease course and had shorter survival with chemotherapy as compared to the non-IgD subtypes, even in this era of novel agents. Considering the rarity of this subtype, international collaborative studies are suggested to confirm our findings and further elucidate the underlying mechanisms for developing potent therapeutic approaches.
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**Additional file 1: Table S1.** Univariate analysis for PFS and OS of 216 patients with multiple myeloma. **Additional file 2: Figure S1.** Kaplan--Meier overall survival curves of patients with multiple myeloma. a: Survival curves of patients stratified according to β~2~M, ≤ 5.5 mg/L vs. \> 5.5 mg/L (*P *= 0.002); b: Survival of patients according to LDH, ≤ 250U/L vs. \> 250U/L (*P *\< 0.001); c: Survival of patients with and without extramedullary infiltration (*P* \< 0.000); d: Survival of patients with and without ISS stage III (*P *= 0.028); e: Survival of patients with and without 13q deletion (*P *= 0.003); f: Survival of patients with and without 1q21 amplification (*P *\< 0.000); g: Survival of patients with and without different IGH rearrangement \[non-IGH rearrangement vs. t(4;14) vs. t(11;14) vs. t(14;16), *P *\< 0.000\]; h: Survival of patients with and without abnormal sFLC ratios (*P *= 0.035). **Additional file 3: Figure S2.** Overall survival in IgD myeloma patients with and without abnormal sFLC ratio.
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